Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports

Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports

Annual-Meeting

4 months
17 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Lower Doses Of Xeloda & Oxaliplatin: Physicians Would Be Happy To Give A Lower Dose If Data Supports.
Up Next Autoplay
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Category: Gastrointestinal Cancer
172 Views
obr 3 months
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
Category: Gastrointestinal Cancer
216 Views
Annual-Meeting 4 months
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Category: Gastrointestinal Cancer
26 Views
Annual-Meeting 4 months
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Category: Gastrointestinal Cancer
126 Views
Annual-Meeting 4 months
Caring For Every Patient And Learning From Every Patient
Caring For Every Patient And Learning From Every Patient
Category: Gastrointestinal Cancer
158 Views
Annual-Meeting 4 months
The Quality and Completeness of Data
The Quality and Completeness of Data
Category: Gastrointestinal Cancer
113 Views
Annual-Meeting 4 months
Financial Toxicity and Equitable Access to Clinical Trials
Financial Toxicity and Equitable Access to Clinical Trials
Category: Gastrointestinal Cancer
64 Views
Annual-Meeting 4 months
Safety Profile for Pembrolizumab
Safety Profile for Pembrolizumab
Category: Gastrointestinal Cancer
20 Views
Annual-Meeting 4 months
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
Category: Gastrointestinal Cancer
77 Views
Annual-Meeting 4 months
Combining Chemo & Immunotherapy Did Not Help Patients: Hope To See Survival Level Off As Data Matures
Combining Chemo & Immunotherapy Did Not Help Patients: Hope To See Survival Level Off As Data Matures
Category: Gastrointestinal Cancer
35 Views
Annual-Meeting 4 months